Related Experiment Video

Updated: Jul 15, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Deoxynortryptoquivaline: A unique antiprostate cancer agent

Yohko Yamazaki1, Manabu Kawada2, Isao Momose1

  • 1Institute of Microbial Chemistry (BIKAKEN), Numazu Branch, Microbial Chemistry Research Foundation, Numazu, 410-0301, Japan.

Oncology Research
|September 25, 2023
PubMed

Insights

Researchers discovered deoxynortryptoquivaline (DNT), a novel compound from fungus, that inhibits prostate cancer growth by suppressing androgen receptor (AR) function without toxicity. This finding offers a new therapeutic strategy for prostate cancer. Keywords: deoxynortryptoquivaline, DNT, androgen receptor, AR, prostate cancer, inhibitor.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The androgen receptor (AR) is a crucial therapeutic target in all stages of prostate cancer.
  • Developing novel AR inhibitors is essential for effective prostate cancer treatment.

Purpose of the Study:

  • To identify novel inhibitors of androgen receptor (AR) function.
  • To explore new therapeutic strategies for prostate cancer targeting AR signaling.

Main Methods:

  • A screening system was developed using androgen-dependent prostate cancer cell lines.
  • 50,000 microbial culture broths were screened for AR inhibitory activity.
  • Purification and characterization of the active compound, deoxynortryptoquivaline (DNT).
  • Assays to determine DNT's mechanism of action, including AR transcriptional activity and nuclear translocation.

Main Results:

  • A fungal fermentation broth was found to inhibit androgen-dependent growth of LNCaP cells without cytotoxicity.
  • Deoxynortryptoquivaline (DNT) was isolated and identified as a novel AR function inhibitor.
  • DNT demonstrated potent inhibition of androgen-dependent prostate cancer cell growth.
  • DNT suppressed AR-dependent transcriptional activity and AR nuclear translocation, but was not an AR antagonist.

Conclusions:

  • Deoxynortryptoquivaline (DNT) is a novel inhibitor of androgen receptor (AR) function.
  • DNT effectively inhibits androgen-dependent prostate cancer cell growth by suppressing AR signaling pathways.
  • DNT represents a promising candidate for further development as a prostate cancer therapeutic agent.
Keywords:
Androgen dependencyAndrogen receptorAnticancer antibioticsProstate cancer

More Related Videos

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents06:43

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents

Published on: August 31, 2013

18.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
320
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
184
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
231